Handeln Liquidia Technologies, Inc. - LQDA CFD

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of novel products which utilize PRINT technology to transform the lives of patients. Its lead product candidate is LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials for the treatment of pulmonary arterial hypertension. The company also develops LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreement with the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.